Cognition Therapeutics Inc — Cash Flow (NASDAQ:CGTX) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Cash from operating activities -3.63 M-18.53 M-16.02 M-28.47 M -29.53 M Cash from investing activities -27 K-171 K-147 K-4 000 — Cash from financing activities 53.2 M5.55 M4.52 M23.57 M 47.35 M Free cash flow -3.66 M-18.7 M-16.16 M-28.48 M -29.53 M

Nachrichten

Cognition Therapeutics bespricht mit FDA nächste Studienphase für Demenz-Medikament

Cognition Therapeutics holds FDA meeting on Lewy bodies dementia drug

Cognition Therapeutics meldet positive Phase-2-Studienergebnisse für DLB-Medikament

Cognition’s DLB drug shows positive results in phase 2 trial

Cognition Therapeutics schließt Patientenrekrutierung für DLB-Studienprogramm ab

Cognition Therapeutics completes enrollment in expanded access program

Cognition Therapeutics skizziert Pläne für Phase-3-Studie mit Alzheimer-Wirkstoff

Cognition Therapeutics outlines Phase 3 plans for Alzheimer’s drug

Cognition Therapeutics: A High-Stakes Bet On A Single Drug - Why I Hold (NASDAQ:CGTX)

Alzheimer-Studie: Cognition Therapeutics erreicht Rekrutierungsziel

Cognition Therapeutics completes enrollment in Alzheimer’s drug trial

Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?